Avid Bioservices

The Cancer Immunotherapy Market 2025-2029 report forecasts significant growth in immuno-oncology therapeutics, highlighting technologies like CAR-T Cells and Checkpoint Inhibitors. It offers insights into market opportunities, key players, and the impact on healthcare, aiming to guide investment and strategic decisions.

The Global Biotechnology Contract Manufacturing Market is projected to grow from USD 15.38 Bn in 2022 to USD 30.87 Bn by 2031, driven by factors like access to expensive technologies, increased flexibility, and speedy product introductions. Key players include Lonza, Samsung Biologics, Thermo Fisher Scientific, and others. The market faces challenges like labeling and packaging issues. The Asia Pacific region shows significant growth potential due to rising R&D investments and healthcare infrastructure improvements.

Opposition to the proposed buyout in the U.S. is increasing, with Roche and Lilly CEOs, unions, consumer groups, and a senator joining the chorus against it.

Astellas' Vyloy, a first-in-class gastric cancer treatment, faced complex development challenges, including manufacturing setbacks and the need for a companion diagnostic from Roche. Dr. Tadaaki Taniguchi, Astellas' chief medical officer, highlights the importance of biomarker identification, diagnostic development, and physician education in precision medicine. The approval of Vyloy alongside Roche's diagnostic underscores the collaborative efforts required in oncology precision medicine. Astellas aims to expand Vyloy's use to pancreatic cancer and continues to explore new treatment modalities in oncology.

Siegfried inaugurates a €XX million, 4,500 sqm R&D center in Evionnaz, Switzerland, aiming to become a premier CDMO. The facility, equipped with advanced technologies, will create 40 high-skilled jobs and complements the Zofingen site, enhancing global research capabilities.

AI is the greatest investment opportunity, poised for exponential growth across industries. Early investors can reap massive rewards, akin to early internet investments. A hidden gem AI company offers potential for 10,000% returns. For $29, gain access to exclusive insights and a year's worth of premium investment research.

Akums Drugs and Pharmaceuticals' Q2 net profit doubled to Rs. 66.65 crore; revenue from operations declined 12.54% YoY. For H1, net profit was Rs. 127.86 crore, compared to a net loss last year; revenue from operations down 4.6% YoY. Adjusted EBITDA and PAT increased sequentially. The company attributes YoY declines to lower API prices and fluctuating demand, aiming for stabilization through expansion. The company focuses on CDMO, API, and branded/generic formulations, recently listing on exchanges after an IPO.

AstraZeneca and Amgen's Tezspire showed efficacy in reducing nasal congestion and nasal polyps in a Phase 3 trial for chronic rhinosinusitis. Jazz Pharmaceuticals plans to start an early-stage study for narcolepsy treatment JZP441 in 2024. Geron secured $250 million, potentially $375 million, for its myelofibrosis drug Rytelo. Aditum Bio and Leads Biolabs formed Oblenio Bio to develop a T cell engager for autoimmune diseases. Gilead Sciences halted Trodelvy development in second-line non-small cell lung cancer, resulting in a $1.8 billion write-down. Avid Bioservices is being taken private by GHO Capital Partners and Ampersand Capital Partners in a $1.1 billion deal.

MilliporeSigma, a Life Science business of Merck KGaA, announces a $76 million expansion of its ADC manufacturing capabilities in St. Louis, tripling capacity and enhancing its CDMO offering. This investment aims to accelerate drug development and bring novel therapies to market more quickly, focusing on targeted oncology treatments.